GLP-1 receptor agonists reduce substance use disorder risk across multiple addiction types in veterans with type 2 diabetes, according to a target trial emulation study published in peer-reviewed research. This finding expands the therapeutic scope of drugs already approved for weight loss and glucose control, creating a new clinical and commercial opportunity for primary care and addiction medicine practices.

The study analyzed veteran populations with type 2 diabetes who initiated GLP-1 therapy and found statistically significant reductions in risks for alcohol use disorder, opioid use disorder, and other substance use disorders compared to matched controls not on GLP-1s. While the mechanism isn't fully understood, preliminary evidence suggests GLP-1 agonists may modulate dopaminergic pathways involved in reward-seeking behavior. This matters because addiction and substance use disorders carry enormous clinical and economic burden—opioid use disorder alone affects roughly 2.7 million Americans, and comorbid diabetes and addiction compounds treatment complexity and cost. Veterans represent a particularly vulnerable cohort, with higher rates of both diabetes and PTSD-related substance abuse.

For primary care practices, DSOs, and hospital systems, this signals a potential reframing of GLP-1 prescribing beyond metabolic disease. Practices treating patients with comorbid type 2 diabetes and active or historical substance use disorders now have evidence-based rationale to discuss GLP-1 therapy as dual-indication treatment. This could drive prescribing volume in primary care and increase patient retention by addressing multiple chronic conditions in a single therapeutic pathway. Addiction medicine specialists and psychiatrists should expect referral volume to shift as primary care becomes more confident in these prescriptions. Risk management teams should also note: as off-label use increases, payers may initially resist covering GLP-1s for addiction-only indications, but this data strengthens the case for expanded coverage.

Watch for formal FDA guidance or expanded labeling language on GLP-1s for substance use disorder treatment, which would accelerate adoption and insurance coverage decisions within 12-18 months.